Goodwin’s Life Sciences team advised Vicebio on its definitive agreement to be acquired by Sanofi (NASDAQ: SNY) for up to $1.6 billion. Under the terms of the agreement, Sanofi will make an upfront payment of $1.15 billion and up to $450 million in development and regulatory milestones. The transaction remains subject to customary closing conditions, including regulatory approvals.
Vicebio is focused on developing next-generation respiratory virus vaccines using the Molecular Clamp technology. The Company was founded with investment from Medicxi and acquired the rights to the Molecular Clamp technology through a license from UniQuest, the commercialisation arm of The University of Queensland, Australia. This proprietary technology was developed by Prof. Paul Young, Prof. Daniel Watterson, and Prof. Keith Chappell at UQ.
The Goodwin team was led Andrew Harrow, Maria Dragun, Kenny Walker-Durrant, Matthew Shelley, Hattie Muncey, Damain Molineus, and Michael Grainger; Tim Worden, Lucy Sharples and Oliver Walker; Anna Humphrey with invaluable support from Dulcie Daly and Matt Rees; Arman Oruc, Paul Jin, Eram Khan, Rebecca Wardle, Justin Pierce, Anuj Ghai and Arom Yun; Duncan Greenhalgh; Alex Fisher and Akshay Chauhan; Curtis McCluskey and Rachel Thurbon; and Grace Wirth.
To learn more, read Vicebio’s official press release.